The influence of drug use on fall incidents among nursing home residents: A systematic review by Sterke, C.S. (Carolyn) et al.
International Psychogeriatrics (2008), 20:5, 890–910 C© 2008 International Psychogeriatric Association
doi:10.1017/S104161020800714X Printed in the United Kingdom
R E V I EW
The influence of drug use on fall incidents
among nursing home residents: a systematic
review
..............................................................................................................................................................................................................................................................................
Carolyn S. Sterke,1,4 Arianne P. Verhagen,2 Ed F. van Beeck3
and Tischa J. M. van der Cammen4
1De StromenOpmaatGroep, Nursing Home Smeetsland, Rotterdam, the Netherlands
2Department of General Practice, Erasmus University Medical Center Rotterdam, the Netherlands
3Department of Public Health, Erasmus University Medical Center Rotterdam, the Netherlands
4Section of Geriatric Medicine, Department of Internal Medicine, Erasmus University Medical Center Rotterdam,
the Netherlands
ABSTRACT
Background: Falls are a major health problem among the elderly, particularly in
nursing homes. Abnormalities of balance and gait, psychoactive drug use, and
dementia have been shown to contribute to fall risk.
Methods:We conducted a systematic review of the literature to investigate which
psychoactive drugs increase fall risk and what is known about the influence
of these drugs on gait in nursing home residents with dementia. We included
studies with a prospective cohort design on psychoactive drug use in nursing
homes with dementia residents and with falls as an outcome measure.
Results: Seventeen studies were included in the review. Pooled risk estimates were
not calculated because there was no homogeneity across studies. We assessed
the strength of evidence for psychoactive drugs as a prognostic factor for falls
by defining four levels of evidence: strong, moderate, limited or inconclusive.
Strong evidence was defined as consistent findings (≥80%) in at least two
high quality cohorts. We found strong evidence that the use of multiple drugs
(3/3 cohorts, effect sizes 1.30–10.30), antidepressants (10/12 cohorts, effect
sizes 1.10–7.60), and anti-anxiety drugs (2/2 cohorts, effect sizes 1.22–1.32)
is associated with increased fall risk. The evidence for the association of other
psychoactive drug classes with fall risk was limited or inconclusive.
Conclusions: Research on the contribution of psychoactive drugs to fall risk in
nursing home residents with dementia is limited. The scarce evidence shows,
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however, that multiple drugs, antidepressants and anti-anxiety drugs increase
fall risk in nursing home populations with residents with dementia.
Key words: falls, gait, psychoactive drugs, dementia, nursing homes
Introduction
Falls are amajor health problem among the elderly, particularly in nursing homes
(Bueno-Cavanillas et al., 2001; Krueger et al., 2001; Jensen et al., 2002; Heinze
et al., 2007). Abnormalities of balance and gait (Tinetti et al., 1988; Speechley
and Tinetti, 1990; Studenski et al., 1994), psychoactive drug use (Tinetti et al.,
1988; Leipzig et al., 1999; Ensrud et al., 2002), and dementia (Morris et al.,
1987; van Doorn et al., 2003) have been shown to contribute to fall risk. Gait
and balance problems usually occur in the more advanced stages of dementia
(Nakamura et al., 1996), and might be due to the use of psychoactive drugs such
as antipsychotics, antidepressants and sedatives (Lord et al., 1995).
It is generally known that nursing home residents with dementia have an
increased fall risk; however, the additive effect of psychoactive drugs to fall risk in
such residents is not known. Also, the mechanisms by which psychoactive drugs
increase fall risk (i.e. the influence on gait) are not known. As a high proportion
of nursing home residents with dementia are treated with psychoactive drugs,
better knowledge of the influence of these medications on fall risk might be
useful to prevent further falls. If we know the influence of psychoactive drugs
on gait, we can use gait measurements to evaluate the influence of drugs on gait
and on subsequent fall risk. We therefore undertook a systematic review of the
literature to investigate which psychoactive drugs increase fall risk and what is
known about the influence of these drugs on gait in nursing home residents with
dementia.
Methods
Search strategy
Between 1980 and 31 October 2007 inclusive we performed a broad
literature search of Medline, Cinahl, Cochrane, and Psychlit. The following
search terms were used: dementia, cognitive impairment, nursing home
resident, elderly, older adult; fall, gait, mobility test; drugs, psychoactive
medication, psychotropics, antidepressants, benzodiazepines, antipsychotics,
sedatives. Randomized controlled trials on drug withdrawal as an intervention
and prospective cohort studies published until November 2007 were eligible for
inclusion in the review.
Study selection
Two reviewers independently performed the study selection (CS and TC).
Differences of opinion were resolved by discussion between the two reviewers.
First, titles and abstracts of identified published articles were reviewed in order to
892 C. S. Sterke et al.
determine their relevance. Next, full papers were screened for eligibility. Studies
were selected if they met the following criteria: (1) residents with dementia were
included in the study population of nursing home residents; and (2) psychoactive
medication use was studied. The outcome measures selected were: (1) falls (our
primary outcome measure), and (2) gait parameters (our secondary outcome
measure, as a possible predictor of risk of falling). If residents with advanced
dementia were excluded from participation in a study, we excluded that study
from our analysis.
The two reviewers (CS and TC) independently appraised each full text
article that passed the first eligibility screening, using a structured form to
record our selection criteria. Excluded studies and reasons for exclusion were
recorded. The references of all identified relevant studies were individually
searched for additional potentially relevant publications. For feasibility reasons,
the publication had to be written in English, French, German or Dutch.
Quality assessment
The two reviewers (CS and TC) assessed the methodological quality of the
studies independently, using the nine-item checklist for quality assessment of
prospective cohort studies from the Dutch Cochrane Center website. Each item
was scored as positive, negative (potential bias), or “not enough information
provided,” if the paper provided insufficient information on a specific item.
Differences in scores were resolved by discussion between the two reviewers,
and a third reviewer (AV) was consulted if disagreements could not be resolved.
At item nine on the checklist it was decided if the results of the study were
valid and applicable. Item nine was scored as positive if six or more items scored
positive. The study was then considered as high quality. Item nine was scored
as dubious or negative if fewer than six items scored positive, and the study was
then considered as low quality.
Data extraction
One reviewer (CS) extracted data concerning population characteristics (mean
age, gender, cognitive status, dementia severity) and sample size using a
structured data collection form. Two reviewers (CS and AV) extracted
information and data regarding primary (falls) and secondary (gait parameters)
outcome measures, determinants (psychoactive drug use), follow-up period,
associations, and adjustments for confounding if reported by the authors, using
a standardized form for data extraction from prospective cohort studies from
the Dutch Cochrane Center website. In case of disagreement, consensus was
achieved by discussion between the two reviewers.
Analysis
The inter-observer agreement of quality assessment was derived by kappa
statistics because of dichotomous values. An inter-observer agreement of
κ = 0.60–0.80 represents a good agreement. An inter-observer agreement of
κ = 0.80–1.00 represents a very good agreement (Landis and Koch, 1977).
Drug-induced falls in dementia: a review 893
Table 1. Levels of evidence for prognostic factors
L E V E L O F
E V I D E N C E
............................................................................................................................................................................................................................................
Strong Consistent findings (≥80%) in at least two high quality cohorts
Moderate One high quality cohort and consistent findings (≥80%) in one or more
low quality cohorts
Limited Findings in one cohort or consistent findings in one or more low
quality cohorts
Inconclusive Inconsistent findings irrespective of study quality
Pooled risk estimates were not calculated because there was no homogeneity
across studies concerning similar drug classes and outcome measures.
Four levels of evidence were defined to assess the strength of evidence for
prognostic factors, i.e. strong, moderate, limited and inconclusive (Table 1).
Strong evidence was defined as consistent findings (≥80%) in at least two
high quality cohorts (Ariens et al., 2000; Sackett et al., 2000). In the case
of dichotomous outcomes, positive clinical relevant findings were considered
relative risks (RRs), odds ratios (ORs) or hazard ratios (HRRs)> 2.0 or< 0.5 or
else significant associations (p< 0.05) (van der Windt et al., 2000). If provided
by the authors, positive findings were derived from the multivariate results. If
only univariate results were available, we used these findings to determine the
level of evidence.
Results
Search strategy
The search of the computerized databases identified a total of 499 citations.
Based on title and abstract, 63 papers were selected, and a full copy of each
paper was applied for and used for the final decision. Screening of the references
of all relevant papers resulted in 20 additional studies, making a total of 83.
Of these, 43 papers were excluded because the design was either a case control
study, or a case report; 20 were excluded because the study population did not
include nursing home residents with dementia or cognitive impairment; and
three because they did not describe psychoactive medication as a determinant
for falls. In 25 of the 66 excluded papers, falls were not described as an outcome
measure. Randomized controlled trials on drug withdrawal as an intervention
were not available.
At the end of this selection process, 17 prospective cohort studies were
included in this systematic review (see Figure 1).
Quality assessment
The two reviewers were in agreement on 135 out of 153 items. The inter-
observer agreement was κ = 0.72. Disagreement occurred mainly because of
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Figure 1. Flow diagram of papers accepted and rejected by the reviewers during the selection procedure
reading errors and interpretation of the methodological criteria list and was
readily resolved. The results of the quality assessment are presented in Table 2.
Most methodological shortcomings concerned the following items: an
insufficient description of the study population (item 1); an insufficient
description of the determinant (item 3); an insufficient description of the
outcome (item 4); is the outcome blinded for the determinant? (item 5); an
insufficiently long follow-up (item 6); and no information on completers versus
loss to follow-up (item 7). Sixteen studies were considered as high quality; one
study was considered as low quality.
Study characteristics
The studies that qualified for inclusion in our review presented their data for total
groups of nursing home residents, without a specific sub-group analysis for those
with dementia or some cognitive impairment. We therefore analyzed the total
groups as this was the nearest possible solution to our initial approach. Table 3
presents a summary of the study characteristics including sample size and
population characteristics; determinants of our interest; outcome; crude and
adjusted estimates with their 95% confidence intervals. Table 3 also provides
information on adjustments for confounding of the final statistical analysis if
reported by the authors.
The sample size varied between n= 78 (Rosendahl et al., 2003) and
n= 43,163 (Avidan et al., 2005). The shortest follow-up period was one month
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Table 2. Results of the quality assessment, showing numeration of the quality items
from the Dutch Cochrane Center checklist
M E THODO L O G I C A L I T EM S
C OHO RT N AM E 1 2 3 4 5 6 7 8 9 QUA L I T Y S C O R E
.............................................................................................................................................................................................................................................
Arfken et al., 2001 1 1 1 1 0 1 ? 1 1 7
Avidan et al., 2005 1 1 1 0 ? 1 1 1 1 7
Capezuti et al., 1996 1 1 1 1 0 1 1 1 1 8
Cooper et al., 2007 0 1 1 1 0 1 ? 1 1 6
Hien et al., 2005 1 1 1 1 0 0 1 1 1 7
Kiely et al., 1998 0 1 1 0 ? 1 1 1 1 6
Kuchynka et al., 2004 0 1 ? 1 0 1 ? 1 ? 4
Lipsitz et al., 1991 1 1 1 1 0 1 1 1 1 8
Lord et al., 2003 0 1 0 1 0 1 1 1 1 6
Ray et al., 2000 1 1 1 1 0 1 1 1 1 8
Ray et al., 2002 1 1 1 1 0 1 1 1 1 8
Rosendahl et al., 2002 1 1 1 1 0 1 0 1 1 7
Ruthazer and Lipzitz, 1993 1 1 1 1 0 0 1 1 1 7
Thapa et al., 1995 1 1 1 1 0 1 1 1 1 8
Thapa et al., 1996 1 1 1 1 ? 1 1 1 1 8
Thapa et al., 1998 1 1 1 1 0 1 1 1 1 8
van Doorn et al., 2003 1 1 1 1 0 1 ? 1 1 7
Quality items: sufficient description study population (item 1); exclusion of selection bias (item 2);
sufficient description determinant (item 3); sufficient description outcome (item 4); is the outcome
blinded for the determinant? (item 5); sufficiently long follow-up (item 6); information on completers
versus loss to follow-up (item 7); information on confounders (item 8); validity results (item 9). Items
are scored as positive scores (1), negative (0), or unclear/insufficient information (?).
(Ruthazer and Lipsitz, 1993; Hien et al., 2005), and the longest was two years
(Lipsitz et al., 1991; van Doorn et al., 2003).
FALLS
Most studies ascertained falls from medical records or nursing home charts and
from incidence reports (Ruthazer and Lipsitz, 1993; Thapa et al., 1995; 1996;
1998; Ray et al., 2000; 2002; Arfken et al., 2001; Lord et al., 2003; Hien et al.,
2005). In one study falls were ascertained from a subject interview (Lipsitz et al.,
1991), and in another from the registration form and reported to a study
nurse (Rosendahl et al., 2003). In four studies falls were ascertained only from
incidence reports (Capezuti et al., 1996; Kuchynka et al., 2004) or nursing home
charts (Kiely et al., 1998; van Doorn et al., 2003; Avidan et al., 2005; Cooper
et al., 2007).
GAIT PARAMETERS
None of the studies described gait parameters as outcome measure for
psychoactive drug use. Some studies described gait parameters as determinants
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Table 3. Summary of study characteristics
C OHO RT P O P U L AT I O N D E T E RM I N A N T S
O U T C OM E
M E A S U R E S
C R U D E
E S T I M AT E S
A N D 9 5% C I
A D J U S T E D
E S T I M AT E S
A N D 9 5% C I N OT E S
........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
Arfken et al.,
2001
Q= 7
N= 368
Memory problems
43.7%
Age± 80
Female± 70%
Antidepressant (Selective
serotonine-reuptake
inhibitor and Non-
Selective
serotonine-reuptake
inhibitor) use
Falls (incident
reports and fall
logs)
Injurious falls
Selective
serotonine-reuptake
inhibitor
OR= 2.01 (1.23–3.28)
Non- Selective
serotonine-reuptake
inhibitor
OR= 1.40 (0.65–3.03)
Selective serotonine-
reuptake inhibitor
OR= 1.77 (1.0–3.13)
Adjusted for age, number of medications,
number of diagnoses, gender, memory
problems, restraints
Avidan et al.,
2005
Q= 7
N= 34163
Moderately-very
severely cognitive
impaired 77.3%
Age 84.2 (7.7)
Female 76.5%
Hypnotic use Falls (The
Resident
Assessment
Instrument/
Minimum Data
Set)
OR= 1.29 (1.13–1.48) OR= 1.13 (0.98–1.30) Adjusted for age, sex, functional status,
cognitive status, intensity of resource
utilization, burden of illness, number
of medications taken, emergency
department visits, and new admission
Capezuti et al.,
1996
Q= 8
N= 322
Severe cognitive
impaired 27.6%
Age± 84 (7.3)
Psychoactive drug use Falls (incidence
reports)
OR= 1.78 (1.14–2.79) Not provided Table provides unadjusted estimates, the
text shows the same figures as adjusted
estimates
Cooper et al.,
2007
Q= 6
N= 177
Age 81.8 (10.7)
Female 79%
No. Psychotropic drug use Falls (patient
charts)
1 psychotropic
RR= 1.8 (1.21–2.84)
2 psychotropics
RR= 3.2 (2.25–4.51)
3 psychotropics
RR= 6.7 (4.15–8.53)
4 psychotropics
RR= 10.3 (6.91–12.8)
van Doorn et al.,
2003
Q= 7
N= 2015
Demented 48.2%
Age 81.4 (7.6)
Female 70.4%
Antipsychotic, Antianxiety,
Antidepressant
medication use
Falls (nursing
home charts)
Antipsychotics
RR= 1.83 (1.48–2.26)
Antianxiety medication
RR= 1.32 (1.01–1.72)
Antidepressants
RR= 1.44 (1.08–1.90)
Not provided
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Hien et al., 2005
Q= 7
N= 898
Mean age 85.7
Female 76%
Antidepressant, Sedatives/
anxiolytics, Typical
antipsychotic,
Olanzapine, Risperidone
use
Falls (incidents
reports and
medical records)
Antidepressants
HR= 1.56 (1.19–2.04)
Sedatives/anxiolytics
HR= 1.37 (1.10–1.72)
Typical antipsychotic
HR= 1.48 (0.96–2.26)
Olanzapine
HR= 2.35 (1.43–3.87)
Risperidone
HR= 1.70 (0.75–3.87)
Antidepressants
HR= 1.45 (1.09–1.93)
Sedatives/anxiolytics
HR= 1.19(0.94–1.50)
Typical antipsychotic
HR= 1.35 (0.87–2.09)
Olanzapine
HR= 1.74 (1.04–2.90)
Risperidone
HR= 1.32 (0.57–3.06)
Adjusted for other psychotropics in the
model, age, sex, type of residential care
facility, length of stay, residential
Classification Scale score, Implicit
illness severity scale, MMSE-score,
Parkinson’s disease, previous falls,
static balance score
Kiely et al., 1998
Q= 6
N= 18855
Cognitive impaired
82%
Median age 87
Female 84%
Antipsychotic
Antianxiety medication use
Falls (The
Resident
Assessment
Instrument/
Minimum Data
Set)
Antipsychotic
OR= 1.21 (1.11–1.33)
Antianxiety
OR= 1.22 (1.11–1.33)
Not provided
Kuchynka et al.,
2004
Q= 4
N= 314
Demented 31.8%
Age± 82
Female 67%
Benzodiazepine use Falls (incidence
reports)
Not provided Not provided Prevalence: 27% of the fallers were
benzodiazepine users, 25% of the
non-fallers were benzodiazepine users
Lipsitz et al.,
1991
Q= 8
N= 126
Cognitive impaired
n= 40
Mean age 87
Female 61%
Antidepressant and
Sedative medication use
Falls (incidence
and computer
reports, medical
records, and
subject
interview)
Antidepressant
OR=5.67 (1.57–20.48)
Sedatives
OR= 1.95 (0.89–4.30)
Antidepressant
OR= 7.6 (1.6–35.3)
Adjusted for Medication variables:
cardiovascular, neuroleptic, sedative,
non-steroidal anti-inflammatory;
Physical examination variables: visual
acuity, impaired hearing, impaired
vibration sensation, impaired position
sensation, impaired touch sensation,
lower extremity muscle weakness,
increased muscle tone, apraxia
combing hair, dysmetria, orthopedic
deformity, orthostatic dizziness,
orthostatic hypotension; Functional
examination variables: unsteady (eyes
open/closed), unsteady (sternal push),
intermittent turning, unsteady turning,
chair stand, broad stance, hesitant gait
initiation, reduced step height, reduced
step length, step asymmetry, step
discontinuity, path deviation, trunkal
instability; Continuous functional gait
variables: chair stand,> 25 steps/20 foot
walk,> 18.8 sec/20 footwalk,> 9.1 sec
to turn 360,> 12 steps to turn
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Table 3. Continued
C OHO RT P O P U L AT I O N D E T E RM I N A N T S
O U T C OM E
M E A S U R E S
C R U D E
E S T I M AT E S
A N D 9 5% C I
A D J U S T E D
E S T I M AT E S
A N D 9 5% C I N OT E S
........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
Lord et al., 2003
Q= 6
N= 228
N=demented?
Age 85 (7.4)
Females 72%
Sedatives
Antipsychotics
Antidepressants
Any psychotropic≥ 2
psychotropics
Falls (incidence
reports and
medical records)
Sedatives
IRR= 1.27 (1.01–1.60)
Antipsychotics
IRR= 1.27 (0.92–1.75)
Antidepressants
IRR= 1.34 (1.05–1.72)
Any psychotropic
IRR= 1.47 (1.20–1.81)
≥ 2 psychotropics
IRR= 1.30 (1.00–1.69)
Any psychotropic
IRR= 1.36 (1.05–1.76)
Adjusted for age, sex, resident
classification score, Implicit illness
severity score, SMMSE, Parkinson’s
disease, stroke, day incontinence, night
incontinence, osteoarthritis in
either/both knees, fall in previous year,
walking aid, ≥4 medications, visual
contrast sensitivity, proprioception,
quadriceps strength, reaction time,
sway-on floor, sway-on foam, static
balance, sit-to-stand ability
Thapa et al.,
1998
Ray et al., 2000
Ray et al., 2002
Q= 8
N= 2428 (Ray 2000
n= 2510)
Mean age 82
Major cognitive
impairment 22%
Female 75%
Benzodiazepine
Antidepressant (Tricyclic
antidepressants, Selective
serotonine-reuptake
inhibitor, and Trazodone
use)
Antipsychotic and other
sedatives/hypnotic
specific drug use
Falls (incidence
reports and
medical records)
Tricyclic
antidepressant
RR= 2.4 (2.1–2.6)
Nortriptyline
RR= 2.3 (2.0–2.5)
Amitriptyline
RR= 2.2 (2.0–2.5)
Doxepin
RR= 2.4 (2.1–2.8)
Imipramine
RR= 2.6 (2.2–3.1)
Other
RR= 3.1 (2.5–3.9)
Tricyclic antidepressant
RR= 2.0 (1.8–2.2)
Nortriptyline
RR= 2.0 (1.8–2.3)
Amitriptyline
RR= 1.9 (1.7–2.1)
Doxepin
RR= 2.0 (1.7–2.3)
Imipramine
RR= 2.2 (1.8–2.6)
Other
RR= 2.4 (1.9–3.0)
Selective serotonine-
reuptake inhibitors
< 20mg
RR= 1.5 (1.3–1.7)
≥ 20mg
RR= 1.9 (1.7–2.2)
Adjusted for age, gender, race, time since
admission to facility and since cohort
entry, body mass index, ambulatory
status, number of activities of daily
living with total dependency,
incontinence, cognitive impairment,
physical restraint use, past falls, use of
anticonvulsants, antiparkinson drugs,
antidepressants, antipsychotics, and
other sedatives
Selective serotonine-
reuptake inhibitors
RR= 2.4 (2.2–2.6)
Paroxetine
RR= 2.3 (2.1–2.6)
Fluoxetine
RR= 2.4 (2.1–2.8)
Sertraline
RR= 2.6 (2.3–3.0)
Selective serotonine-
reuptake inhibitors
RR= 1.8 (1.6–2.0)
Paroxetine
RR= 1.7 (1.5–1.9)
Fluoxetine
RR= 1.8 (1.6–2.1)
Sertraline
RR= 1.8 (1.5–2.1)
Trazodone< 50mg
RR= 1.5 (1.2–1.8)
≥ 50mg
RR= 1.1 (1.0–1.3)
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Trazodone
RR= 1.9 (1.7–2.1)
Trazodone
RR= 1.2 (1.0–1.4)
Baseline
benzodiazepines
RR= 1.02 (0.95–1.10)
Tricyclic antidepressant
≤ 10mg
RR= 1.2 (1.0–1.5)
11–25mg
RR= 2.0 (1.8–2.3)
26–50mg
RR= 2.1 (1.8–2.3)
> 50mg
RR= 2.4 (2.1–2.8)
Current
benzodiazepines
RR= 1.44 (1.33–1.56)
Dose current users
≤ 2mg
RR= 1.30 (1.12–1.52)
2.01–4mg
RR= 1.34 (1.20–1.51)
4.01–8mg
RR= 1.38 (1.20–1.51)
> 8mg
RR= 2.21 (1.89–2.60)
Days since start of
use< 7
RR= 2.96 (2.33–3.75)
7–29
RR= 2.23 (1.64–3.03)
≥ 30
RR= 1.30 (1.17–1.44)
Elimination half-life,
hours< 12
RR= 1.15 (0.94–1.40)
12–23
RR= 1.44 (1.33–1.59)
≥ 24
RR= 1.73 (1.40–2.14)
Daytime falls Current benzodiazepine
use
RR= 1.38 (1.25–1.51)
Elimination half-life,
hours< 12
RR= 0.90 (0.70–1.17)
12–23
90
0
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Table 3. Continued
C OHO RT P O P U L AT I O N D E T E RM I N A N T S
O U T C OM E
M E A S U R E S
C R U D E
E S T I M AT E S
A N D 9 5% C I
A D J U S T E D
E S T I M AT E S A N D
9 5% C I N OT E S
........................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
RR= 1.43 (1.29–1.59) ≥ 24
Nighttime falls Current benzodiazepine use
RR= 1.83 (1.55–2.15)
Elimination half-life, hours< 12
RR= 2.19 (1.59–3.03) 12–23
RR= 1.68 (1.39–2.02) ≥ 24
RR= 1.80 (1.14–2.83)
Rosendahl et al.,
2003
Q= 7
N= 78
Demented 47%
Age 81 (6)
Female 72%
Tranquilizers/sedatives
Antidepressant use
Falls (register form
and reported to
study nurse)
Tranquillizers/
sedatives
HR= 1.66 (0.93–2.96)
Antidepressants
HR= 1.93 (1.05–3.52)
Not provided
Ruthazer and
Lipsitz, 1993
Q= 7
N= 635
N=demented ?
Mean age 88.7
Female 77%
Antidepressant,
Antipsychotic,
Benzodiazepine use
Falls
(computerized
documentation
systems and
chart reviews)
Antidepressants
(women)
OR= 1.95 (1.02–3.70)
Adjusted estimate
Antidepressants (women)
OR= 1.84 (0.91–3.69)
Stratified for sex. Adjusted
for age and fall history
Thapa et al.,
1995
Q= 8
N= 282
Moderate – severely
cognitive impaired
68.8%
Age 80.9
Female 72%
Any psychotropic drug
Antipsychotics
Benzodiazepines
Cyclic antidepressants
Other anxiolytics/hypnotics
Multiple psychotropic
drug use
Recurrent falls≥ 2
(incidence
reports and
nursing home
charts)
Any psychotropic drug
IDR= 1.67 (1.10–2.5)
Antipsychotics
IDR= 1.54 (0.88–2.7)
Benzodiazepines
IDR= 1.70 (0.96–2.9)
Cyclic antidepressants
IDR= 1.98 (0.97–4.0)
Other anxiolytics /
hypnotics
IDR= 1.26 (0.57–2.7)
Multiple psychotropic
drugs
IDR= 1.89 (1.10–3.2)
Adjusted incidence density
ratios
Any psychotropic drug
IDR= 1.97 (1.28–3.05)
Antipsychotics
IDR= 1.48 (0.79–2.78)
Benzodiazepines
IDR= 2.10 (1.17–3.76)
Cyclic antidepressants
IDR= 2.92 (1.39–6.16)
Other anxiolytics / hypnotics
IDR= 1.23 (0.55–2.76)
Multiple psychotropic drugs
IDR= 2.57 (1.45–4.57)
Adjusted for age, assisted
activities of daily living,
balance score, symptoms of
dementia and depression, other
psychotropic drug use.
Thapa et al.,
1996
Q= 8
N= 503
Moderate and Severe
cognitive impaired
n= 218
Age 37.2%≥ 85
Female 73%
Psychotropic drug use
(Antipsychotics,
Benzodiazepines, Cyclic
antidepressants/
Trazodone, other
Hypnotics/ anxiolytics)
Injurious falls
(incidents
reports and
nursing home
charts)
Unadjusted incidence
rates, per 100 person
years
Psychotropic drugs
IDR= 23.4
Adjusted incidence density
ratios
Psychotropic drugs
IDR= 2.49 (1.43–4.33)
Adjusted for age, gender, BMI,
cognitive impairment
Note: Q=quality score; OR= odds ratio; RR= relative risk; HR=hazard ratio; IRR= incidence rate ratio; IDR= incidence density ratio.
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for falls (Lipsitz et al., 1991; Lord et al., 2003; Rosendahl et al., 2003; van Doorn
et al., 2003; Kuchynka et al., 2004).
PSYCHOACTIVE DRUG USE
In most studies drug use is the determinant of primary interest (Ruthazer
and Lipsitz, 1993; Thapa et al., 1995; 1996; 1998; Ray et al., 2000; 2002;
Arfken et al., 2001; Avidan et al., 2005; Hien et al., 2005; Cooper et al., 2007).
In other studies psychoactive drugs are studied among other risk factors to
develop or to evaluate a fall risk model (Lipsitz et al 1991; Kiely et al., 1998;
Lord et al., 2003; Rosendahl et al., 2003). One study described the effect of
restraint use on falls, with drug use being a confounder in their multiple logistic
regression model (Capezuti et al., 1996). In another study, dementia is the factor
of primary interest. Other variables, including antipsychotic, anti-anxiety and
antidepressant drug use were evaluated as potential confounders (van Doorn
et al., 2003).
TheMinimumData Set (MDS;Morris et al., 1990) was used by most studies
to ascertain psychoactive drug use (Kiely et al., 1998; van Doorn et al., 2003;
Avidan et al., 2005). Other studies used pharmacy records (Arfken et al., 2001;
Cooper et al., 2007), medical records (Lord et al., 2003; Hien et al., 2005),
or medication administration records (Lipsitz et al 1991; Ruthazer and Lipsitz,
1993; Thapa et al., 1995; 1996; Capezuti et al., 1996; Ray et al., 2000; 2002).
Some studies provided information on dose or duration of use (Capezuti et al.,
1996; Thapa et al., 1998; Ray et al., 2000; 2002). In one study, psychoactive drug
use was calculated as the proportion of days when psychoactive drugs were used
divided by the number of days the resident was present in the nursing home;
drug use was categorized by degrees of use as “none,” “some” (1–98 days),
and “all” (daily use) (Capezuti et al., 1996). In two studies, benzodiazepine use
was classified for each day of follow-up as “current” (taken that day), “recent”,
or “none” (Ray et al., 2000; 2002). One study considered dose, duration and
elimination half-life in relation to falls. Elimination half-life was also considered
in relation to daytime and night-time falls (Ray et al., 2000). In one study
any recent change in medication and the time when medications were taken in
relation to the fall were recorded, and a blood sample was obtained to check any
relevant drug level (Lipsitz et al., 1991). In only one study is it unclear as to how
drug use was ascertained (Kuchynka et al., 2004).
ASSOCIATIONS
Eleven publications presented the associations between psychoactive drug use
and falls in adjusted estimates: OR (Lipsitz et al., 1991; Ruthazer and Lipsitz,
1993; Arfken et al., 2001; Avidan et al., 2005); RR (Thapa et al., 1998; Ray et al.,
2000; 2002); incidence density ratio (IDR; Thapa et al., 1995; 1996), HR (Hien
et al., 2005), and incidence rate ratio (IRR; Lord et al., 2003). One study
stratified for sex (Ruthazer and Lipsitz, 1993). Five publications presented only
crude estimates of the associations between psychoactive drug use and falls: OR
(Capezuti et al., 1996), RR (Kiely et al., 1998; van Doorn et al., 2003; Cooper
et al., 2007), and HR (Rosendahl et al., 2003). One publication only presented
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the prevalence of fallers among benzodiazepine users and among non-users
(Kuchynka et al., 2004).
All publications presented their results for residents with and without
dementia together. None of the studies provided a sub-group analysis of the
estimates in the population of nursing home residents with dementia. In five
studies, it was unclear which proportion of the population had dementia
(Ruthazer and Lipsitz, 1993; Ray et al., 2000; Lord et al., 2003; Hien et al.,
2005; Cooper et al., 2007). In two publications, the estimates for the whole
cohort – both those in nursing homes and in intermediate care facilities – were
given. In these studies there was no sub-group analysis of the estimates of the
proportion of the population in the nursing homes (Lord et al., 2003; Hien
et al., 2005).
Level of evidence
The heterogeneity of the study population and determinants necessitated a
qualitative summary of the results. Table 4 presents a summary of the available
evidence for the use of psychoactive drugs and its association with falls in nursing
home populations including residents with dementia. Three papers classified all
psychoactive drugs together, regardless of specific drug class (Capezuti et al.,
1996; Thapa et al., 1996; Cooper et al., 2007). All other studies presented
data by drug class; they are presented both in the psychoactive and in the
individual drug summary of the results. The results of studies that presented
data on benzodiazepines, hypnotics, sedatives and anti-anxiety drugs were also
summarized together and for the individual drug classes. Three papers provided
data on the antidepressant class (Thapa et al., 1995; 1998; Arfken et al., 2001);
they are presented in both the antidepressant and the individual antidepressant
class summary.
ANY PSYCHOACTIVE DRUG
The overall evidence that the use of any psychoactive drug increases fall risk in
nursing home residents with dementia is inconclusive. The reported strength of
the associations varied widely (ORs and RRs 0.90–7.6). Positive findings were
found in 28 out of 42 (67%) of the studies. The evidence that any psychoactive
drug increases recurrent falls is limited. We found only one study in which the
use of psychoactive drugs increased the risk of recurrent falls (Thapa et al.,
1995). The evidence for injurious falls is strong. Positive findings were found
in two studies (n= 503, IDR 2.49 and n= 368, OR 1.77) (Thapa et al., 1996;
Arfken et al., 2001).
BENZODIAZEPINES AND OTHER HYPNOTIC, SEDATIVE OR
ANTI-ANXIETY DRUGS
For the whole spectrum of benzodiazepines or any other hypnotic, sedative or
anti-anxiety drug, we found that the overall evidence that these drugs increase
the risk of falls or recurrent falls is inconclusive. Positive findings for the risk of
falls were found in five out of 11 cohorts (45%) (range of ORs and RRs 1.13–
2.4) (Thapa et al., 1995; 1998; Kiely et al., 1998; van Doorn et al., 2003; Lord
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Table 4. Qualitative summary of the available evidence
P S Y C H OAC T I V E
D R U G S O U T C OM E
C OHO RT
A S S E S S E D + F I N D I N G S
+ H I G H
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QUA L I T Y − F I N D I N G S
− H I G H
QUA L I T Y
− L OW
QUA L I T Y
L E V E L O F
E V I D E N C E
.....................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
Any psychoactive drug Falls 42 28/42 (67%) 28 – 14/42 (33%) 13 1 Inconclusive
Recurrent falls 1 1/1 (100%) 1 – – – – Limited yes
Injurious falls 2 2/2 (100%) 2 – – – – Strong yes
Hypnotics Falls 11 5/11 (45%) 5 6/11 (55%) 5 1 Inconclusive
Sedatives Recurrent falls 2 1/2 (50%) – – 1/2 (50%) – – Inconclusive
Anti-anxiety
Benzodiazepines
Hypnotics Falls 2 – – – 2/2 (100%) 2 – Strong no
Recurrent falls 1 – – – 1/1 (100%) 1 – Limited no
Sedatives Falls 4 1/4 (25%) 1 – 3/4 (75%) 3 – Inconclusive
Anti-anxiety Falls 2 2/2 (100%) 2 – – – – Strong yes
Benzodiazepines Falls 3 2/3 (67%) 2 – 1/3 (33%) – 1 Inconclusive
Recurrent falls 1 1/1 (100%) 1 – – – – Limited yes
Daytime falls 1 1/1 (100%) 1 – – – – Limited yes
Night-time falls 1 1/1 (100%) 1 – – – – Limited yes
Benzodiazepine use
elimination
half-life< 12 hours
Falls 1 – – – 1/1 (100%) 1 – Limited no
Daytime falls 1 – – – 1/1 (100%) 1 – Limited no
Night-time falls 1 1/1 (100%) 1 – – – – Limited yes
Benzodiazepine use
elimination
half-life≥ 12 hours
Falls 1 1/1 (100%) 1 – – – – Limited yes
Daytime falls 1 1/1 (100%) 1 – – – – Limited yes
Night-time falls 1 1/1 (100%) 1 – – – – Limited yes
Antipsychotics Falls 7 3/7 (43%) 3 – 4/7 (57%) 3 – Inconclusive
Recurrent falls 1 – – – 1/1 (100%) 1 – Limited no
Typical antipsychotics Falls 1 – – – 1/1 (100%) 1 – Limited no
Risperidone Falls 1 – – – 1/1 (100%) 1 – Limited no
Olanzapine Falls 1 1/1 (100%) 1 – – – – Limited yes
Antidepressant Falls 12 10/12 (83%) 10 – 2/12 (17%) 2 – Strong yes
Tricyclic
antidepressant
Falls 2 2/2 (100%) 2 – – – – Strong yes
Recurrent falls 1 1/1 (100%) 1 – – – – Limited yes
SSRI Falls 2 2/2 (100%) 2 – – – – Strong yes
Injurious falls 1 1/1 (100%) 1 – – – – Limited yes
Non-SSRI Falls 1 – – – 1/1 (100%) 1 – Limited no
Trazodone Falls 1 1/1 (100%) 1 – – – – Limited yes
Multiple psychotropic
drugs
Falls 3 3/3 (100%) 3 – – – – Strong yes
Recurrent falls 1 1/1 (100%) 1 – – – – Limited yes
Positive findings: the association between the use of psychoactive drugs and falls is strong (OR, RR or HRR >2.0 or< 0.5 or significant, p< 0.05).
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et al., 2003). Positive findings for the risk of recurrent falls were found in one
out of two (50%) cohorts (Thapa et al., 1995). However, when we examined
these drugs separately, the evidence for the individual drug classes differed from
the overall evidence. Based on only one cohort, we found limited evidence that
benzodiazepines increase the risk of recurrent falls (Thapa et al., 1995), and
that intermediate- and long-acting benzodiazepines increase overall fall risk. We
also found limited evidence that short-acting benzodiazepines increase fall risk
at night-time but not during the day (Ray et al., 2000). For the whole spectrum
of benzodiazepines, the individual effects described above disappear.
Furthermore, we found strong evidence that the use of anti-anxiety drugs
increases fall risk. Positive findings were found in two out of two studies
(n= 2015, RR 1.32 and n= 18,855, OR 1.22) (van Doorn et al., 2003; Kiely
et al., 1998).
We found inconclusive evidence for the use of sedatives. Positive findings were
found in only one out of four studies (Lord et al., 2003).
There is strong evidence that the use of hypnotics does not increase fall risk.
In the two studies we included, there were no significant associations found
between the use of hypnotics and (recurrent) falls (n= 34,163, OR 1.13 (0.98–
1.30) and n= 282, IDR= 1.23 (0.55–2.76) (Avidan et al., 2005 and Thapa et al.,
1995, respectively).
ANTIPSYCHOTICS
The evidence that antipsychotics increase fall risk is inconclusive. Positive
findings were found in three out of seven (43%) cohorts (Kiely et al., 1998;
van Doorn et al., 2003; Hien et al., 2005). However, after stratification by type
of antipsychotic, there is limited evidence that olanzapine use increases fall risk,
and limited evidence that risperidone and typical antipsychotics do not increase
fall risk. There is limited evidence that antipsychotics do not increase the risk of
recurrent falls (Hien et al., 2005).
ANTIDEPRESSANTS
There is strong evidence that the use of antidepressants increases fall risk. In
10 out of 12 (83%) cohorts significant associations were found (n= 78–2428,
range of effect sizes 1.1–7.6) (Lipsitz et al., 1991; Thapa et al., 1995; 1998;
Arfken et al., 2001; van Doorn et al., 2003; Lord et al., 2003; Rosendahl et al.,
2003; Hien et al., 2005). After stratification by the categories of antidepressants,
the evidence that the use of tricyclic antidepressants (2/2 cohorts, n= 282, IDR
2.96 and n= 2428, RR 2.0) (Thapa et al., 1995; 1998) and the use of SSRIs
(2/2 cohorts, n= 368, OR 2.01 and n= 2428, RR 1.8) (Arfken et al., 2001;
Thapa et al., 1998) increase fall risk remains strong. The evidence that the use
of trazodone increases fall risk is limited (Thapa et al., 1998).
MULTIPLE PSYCHOTROPIC DRUGS
There is strong evidence that multiple psychoactive drug use increases fall risk
(3/3 studies, n= 177–282, range of RR 1.30–10.3) (Thapa et al., 1995; Lord
et al., 2003; Cooper et al., 2007). One study classifiedmultiple drugs as the use of
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two psychotropics (RR 3.2), three psychotropics (RR 6.7) or four psychotropics
(RR 10.3) (Cooper et al., 2007). The evidence for recurrent falls is limited
(Thapa et al., 1995).
Discussion
This systematic review has summarized the results of 17 prospective cohort
studies concerning the influence of psychoactive drug use on fall risk and
the influence of these drugs on gait parameters in nursing home populations
with residents who have dementia. Substantial heterogeneity across studies
for determinant measures, outcome measures, statistical analysis and data
presentation was found. This heterogeneity impeded sensible statistical pooling
of results; hence, a qualitative summary was undertaken. Strong evidence was
found for the use of multiple psychotropic drugs, antidepressants and anti-
anxiety drugs to increase fall risk. Strong evidence was found that hypnotics did
not increase fall risk. The reported strength of the associations varied widely in
the evidence for multiple psychotropic drugs (RR 1.30–10.3). The strength of
the significant association seems to be moderate in one study (RR= 1.30) (Lord
et al., 2003), whereas in another study the strength is larger (RR= 10.3) for the
concurrent use of four psychotropics (Cooper et al., 2007). The evidence was
based on three smaller cohorts (Thapa et al., 1995; Lord et al., 2003; Cooper
et al., 2007). The conclusion of strong evidence that the use of anti-anxiety
drugs increases fall risk is based on only two cohorts. Although the strength
of the associations in these two cohorts is moderate (RR 1.32, OR 1.22), the
two cohorts were large (Kiely et al., 1998; van Doorn et al., 2003). The strong
evidence for the use of antidepressants is based on 10 cohorts (Lipsitz et al.,
1991; Thapa et al., 1995; 1998; Arfken et al., 2001; van Doorn et al., 2003;
Lord et al., 2003; Rosendahl et al., 2003; Hien et al., 2005), with the strongest
association (OR= 7.6) being found in a relatively small cohort (n= 126 women)
(Lipsitz et al., 1991). In the largest cohort (n= 2428) only a weak association
was found (RR= 1.1) (Thapa et al., 1998).
For other drug classes, the evidence was limited or inconclusive. Limited
evidence was always because the evidence was based on only one cohort.
It is generally recommended to prescribe benzodiazepines with a short
elimination half-life to older persons. However, these were found to increase
night-time falls (Thapa et al., 1995), which can be particularly hazardous.
Intermediate- and long-acting benzodiazepines were found to increase overall
fall risk (Thapa et al., 1995).
An earlier review on the association between psychoactive drugs and
falls found an increased fall risk for all psychoactive drugs (Leipzig et al.,
1999). However, the Leipzig review was performed in the general population,
not exclusively in nursing home residents. Possible explanations for these
inconsistent findings might lie with our different methodology and review
criteria, and with our qualitative summary using levels of evidence. We only
included papers with a prospective study design because this is considered to
be the optimal design to identify the presence of prognostic factors and their
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associations with the outcome (Altman, 2001). The Leipzig review also included
studies with a cross-sectional and a case control study design (Leipzig et al.,
1999).
Limitations of this review
The lack of homogeneity across the studies impeded sensible statistical pooling
of data. This is a limitation of our study, as we had to define levels of evidence
based on the strength of positive and negative findings across the studies for
each medication type or group, and each outcome. A particular limitation of
this approach is that the strength of findings is not strengthened or ameliorated
depending upon the sample size, which is an important influence when pooled
data is incorporated into a meta-analysis. A large study with a moderate positive
effect contributes substantially more to a pooled effect size than does a small
sample study with the same positive effect.
The fact that none of the studies we included presented a sub-group analysis
of the estimates in the population of nursing home residents with dementia could
have biased our conclusions. The exact contribution of psychoactive drug use to
fall risk in nursing home residents with dementia is not yet known.
Also, the presentation of the different drug classes in the papers could have
biased our conclusions. Some papers classified all psychoactive drugs together,
regardless of specific drug class. Furthermore, the difference between anti-
anxiety, sedative and hypnotic characteristics of psychoactive drugs is often
a matter of dose and of elimination half-life. In general, benzodiazepines are
prescribed as a hypnotic, anti-anxiety drug or sedative. The overall level of
evidence for benzodiazepines is inconclusive, which may be due to the fact that
there is strong evidence that anti-anxiety drugs increase fall risk and limited
evidence that intermediate- and long-acting benzodiazepines increase fall risk,
and that there is strong evidence that hypnotics do not increase fall risk and
limited evidence that short-acting benzodiazepines do not increase fall risk.
Levels of evidence in this review were based on positive findings from
multivariate or univariate results. The use of univariate results when multivariate
results were not available could have biased our conclusions regarding the level of
available evidence. Overestimation of the estimates may occur because univariate
results are not adjusted for potential confounding.
The possibility of publication bias cannot be excluded. One cohort published
three articles (Thapa et al., 1998; Ray et al., 2000; 2002). Studies with significant
results are more likely to lead to multiple publications. Furthermore, relevant
studies hidden in unknown databases are difficult to locate and therefore may
have been missed.
Validity of the studies in the review
Information bias can result from differential and non-differential misclassific-
ation and can influence the estimate of the strength of the association. The
incidence reports and medical records from which falls were ascertained may
not be complete. On the other hand, a recorded fall may not be a fall according
Drug-induced falls in dementia: a review 907
to the definition, as acute medical conditions may have been involved in the
population under study (Kellogg International Work Group, 1987).
Misclassification of drug use may result when drug use is ascertained
only from medical records and when it is not assured that medications were
actually administered. Baseline measurement of drug use can induce substantial
misclassification. One study found that this misclassification caused substantial
underestimation of the association of benzodiazepine use with fall risk (Ray et al.,
2002).
Finally, selective loss to follow-up cannot be excluded in all studies. In one
cohort, residents were followed through the day of facility exit, defined as
discharge, death or transfer or a hospital stay of more than 14 days (Thapa
et al., 1998; Ray et al., 2000; 2002).
Conclusions and recommendations
In summary, we conclude that the studies conducted within the period covered
by this review consistently show an increased fall risk for the use of multiple
drugs, antidepressants and anti-anxiety drugs in nursing home populations with
residents with dementia. The evidence for other psychoactive drug classes is
limited or inconclusive. Our initial approach was to analyze the data of nursing
home residents with dementia only. However, none of the studies we found used
a sub-group analysis for this specific group of residents.
It is generally accepted that falls are an intrinsic component of dementia and
living in a nursing home. However, because of the multi-morbidity of this patient
group, we do not knowwhich risk factors are (potentially) reversible. The relative
contribution of each drug class is not clear from the current literature. Also, little
is known about dose and duration of use in relation to fall risk.
It was revealing to discover how little is known about the influence of
psychoactive drugs on gait parameters in nursing home residents with dementia.
As drugwithdrawal has been shown to reduce fall risk (Campbell et al., 1999) and
improve mobility tests in community-dwelling older persons without dementia
(van der Velde et al., 2007a; 2007b), it is important to know the effect of
psychoactive drugs on gait in nursing home residents with dementia. Falls due
to psychoactive drug use might be caused by impairment of mobility generated
by these drugs (Lord et al., 1995). If gait can be improved by withdrawal of
these drugs, a number of falls might be prevented, even among nursing home
residents. Gait measurements may be useful in the clinical follow-up of fallers in
whom these drugs are withdrawn. Large prospective studies on the relationship
between psychoactive drugs and gait in nursing home residents with dementia
are needed, and should focus on the contribution of each drug class and dose
and duration of use on fall risk.
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